Clinical trial · Expanded Access

IFx-Hu2.0 Expanded Access Program

NCT04853602CI-TRIAL-00079696availableClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

Expanded access requests for IFx-Hu2.0 may be considered for the treatment of adult patients (greater than or equal to 18 years of age) with stage III through IV cutaneous melanoma, advanced Merkel cell carcinoma (MCC), or advanced cutaneous squamous cell carcinoma (cSCC) who have failed all available treatment options. To request access, use Responsible Party contact information provided in this record..

Conditions

Conditions (4)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Cutaneous Melanoma, Stage III	Cutaneous Melanoma	CURATED_BROADER	0.78
Cutaneous Melanoma, Stage IV	Cutaneous Melanoma	CURATED_BROADER	0.78
Cutaneous Squamous Cell Carcinoma	Skin Squamous Cell Carcinoma	ALIAS	0.90
Merkel Cell Carcinoma	Merkel Cell Carcinoma	ONTOLOGY_EXACT	0.98

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
IFx-Hu2.0	Biological	—	UNRESOLVED

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

Inclusion Criteria:

* To request more information use Responsible Party contact information provided in this record

Exclusion Criteria:

* To request more information use Responsible Party contact information provided in this record

References

Publications (1)

BACKGROUNDBunch BL, Kodumudi KN, Scott E, Morse J, Weber AM, Berglund AE, Pilon-Thomas S, Markowitz J. Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model. Cancer Immunol Immunother. 2020 Dec;69(12):2465-2476. doi: 10.1007/s00262-020-02634-4. Epub 2020 Jun 18. PMID 32556443